Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | CCKAR | P32238 | 3/20 | 0.45 |
| ▸ | CCKBR | P32239 | 3/20 | 0.45 |
| ▸ | CHRND | Q07001 | 3/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
| ▸ | CHRNG | P07510 | 1/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPRA | P18433 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630355 | 0.96 | CHRND (0.47) | OPRD1OPRM1OPRK1CHRNDCHRNA1 | |
| SCHEMBL29630352 | 0.87 | MME (0.48) | CHRNDCHRNA1CHRNGCHRNB1PTPN1 | |
| SCHEMBL7586744 | 0.87 | CHRND (0.55) | OPRD1OPRM1OPRK1CHRNDCHRNA1 | |
| SCHEMBL3952781 | 0.87 | CHRND (0.55) | OPRD1OPRM1OPRK1CHRNDCHRNA1 | |
| SCHEMBL29630576 | 0.86 | OPRD1 (0.55) | OPRD1OPRM1OPRK1CHRNDCHRNA1 | |
| SCHEMBL30468670 | 0.85 | CHRND (0.47) | CHRNDCHRNA1CHRNGCHRNB1GRIA1 | |
| SCHEMBL29707530 | 0.85 | CHRND (0.47) | CHRNDCHRNA1CHRNGCHRNB1GRIA1 | |
| SCHEMBL30111298 | 0.85 | OPRD1 (0.48) | OPRD1OPRM1OPRK1CHRNDCHRNA1 | |
| SCHEMBL31198202 | 0.84 | MEN1 (0.52) | CHRNDCHRNA1CHRNGCHRNB1PTPN1 | |
| SCHEMBL29540311 | 0.83 | NAALAD2 (0.59) | OPRD1OPRM1OPRK1CHRNDCHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | OPRD1 4566/4885OPRM1 4101/4885OPRK1 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.